Modeling Ewing sarcoma tumors in vitro with 3D scaffolds

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages 6500-6505

  Fong, Eliza Li Shan ^a   Lamhamedi Cherradi, Salah Eddine ^b   Burdett, Emily ^a   Ramamoorthy, Vandhana ^b   Lazar, Alexander J ^b   Kasper, F Kurtis ^a   Farach Carson, Mary C ^c   Vishwamitra, Deeksha ^b   Demicco, Elizabeth G ^d   Menegaz, Brian A ^b   Amin, Hesham M ^b   Mikos, Antonios G ^a   Ludwig, Joseph A ^b  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RICE UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOXORUBICIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYCAPROLACTONE; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; EWING SARCOMA; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR MODEL;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CAPROATES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; MICE; MICE, KNOCKOUT; MICE, SCID; MICROSCOPY, ELECTRON, SCANNING; RECEPTORS, SOMATOMEDIN; SARCOMA, EWING; TISSUE CULTURE TECHNIQUES; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84876234682     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1221403110     Document Type: Article

References (38)

1. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1(1):46-54.
2. Jacks T, Weinberg RA (2002) Taking the study of cancer cell survival to a new dimension. Cell 111(7):923-925.
3. Weaver VM, et al. (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137(1):231-245.
4. Fischbach C, et al. (2007) Engineering tumors with 3D scaffolds. Nat Methods 4(10): 855-860.
5. Kunz-Schughart LA (1999) Multicellular tumor spheroids: Intermediates between monolayer culture and in vivo tumor. Cell Biol Int 23(3):157-161.
6. Friedrich J, Ebner R, Kunz-Schughart LA (2007) Experimental anti-tumor therapy in 3D: Spheroids-old hat or new challenge? Int J Radiat Biol 83(11-12):849-871.
7. Weigelt B, Bissell MJ (2008) Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 18(5):311-321.
8. Lawlor ER, Scheel C, Irving J, Sorensen PH (2002) Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 21(2): 307-318.
9. Kang HG, et al. (2007) E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 67(7):3094-3105.
10. David L, et al. (2008) Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity. Acta Biomater 4(2):256-263.
11. Chitcholtan K, Sykes PH, Evans JJ (2012) The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med 10:38.
12. Bates RC, Edwards NS, Yates JD (2000) Spheroids and cell survival. Crit Rev Oncol Hematol 36(2-3):61-74.
13. Fischbach C, et al. (2009) Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc Natl Acad Sci USA 106(2):399-404.
14. Verbridge SS, Chandler EM, Fischbach C (2010) Tissue-engineered three-dimensional tumor models to study tumor angiogenesis. Tissue Eng Part A 16(7):2147-2152.
15. Liu H, Radisky DC, Wang F, Bissell MJ (2004) Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 164(4):603-612.
16. Kenny PA, et al. (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1(1): 84-96.
17. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122(1):35-43.
18. Muranen T, et al. (2012) Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21(2):227-239.
19. Lee SJ, Atala A (2013) Scaffold technologies for controlling cell behavior in tissue engineering. Biomed Mater 8(1):010201.
20. Thibault RA, Scott Baggett L, Mikos AG, Kasper FK (2010) Osteogenic differentiation of mesenchymal stem cells on pregenerated extracellular matrix scaffolds in the absence of osteogenic cell culture supplements. Tissue Eng Part A 16(2):431-440.
21. Liao J, Guo X, Nelson D, Kasper FK, Mikos AG (2010) Modulation of osteogenic properties of biodegradable polymer/extracellular matrix scaffolds generated with a flow perfusion bioreactor. Acta Biomater 6(7):2386-2393.
22. Mountziaris PM, Tzouanas SN, Mikos AG (2010) Dose effect of tumor necrosis factor-alpha on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds. Biomaterials 31(7):1666-1675.
23. Zhang YZ, Su B, Venugopal J, Ramakrishna S, Lim CT (2007) Biomimetic and bioactive nanofibrous scaffolds from electrospun composite nanofibers. Int J Nanomedicine 2(4):623-638.
24. Cipitria A, Skelton A, Dargaville TR, Dalton PD, Hutmacher DW (2011) Design, fabrication and characterization of PCL electrospun scaffolds-a review. J Mater Chem 21(26):9419-9453.
25. Pham QP, Sharma U, Mikos AG (2006) Electrospun poly(epsilon-caprolactone) microfiber and multilayer nanofiber/microfiber scaffolds: Characterization of scaffolds and measurement of cellular infiltration. Biomacromolecules 7(10):2796-2805.
26. Olmos D, et al. (2011) Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: Reality and expectations. Sarcoma 2011:402508.
27. Ludwig JA, Lamhamedi-Cherradi S-E, Lee H-Y, Naing A, Benjamin R (2011) Dual targeting of the insulin-like growth factor and collateral pathways in cancer: Combating drug resistance. Cancers 3(3):3029-3054.
28. Scotlandi K, et al. (1996) Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res 56(20):4570-4574.
29. Scotlandi K, et al. (1998) Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58(18):4127-4131.
30. Scotlandi K, et al. (2002) Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 9(3):296-307.
31. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ (1997) The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 272(49):30822-30827.
32. Naing A, et al. (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18(9):2625-2631.
33. Schwartz GK, et al. (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial. Lancet Oncol, 10.1016/s1470-2045(13)70049-4.
34. Olive PL, Durand RE (1994) Drug and radiation resistance in spheroids: Cell contact and kinetics. Cancer Metastasis Rev 13(2):121-138.
35. Burdett E, Kasper FK, Mikos AG, Ludwig JA (2010) Engineering tumors: A tissue engineering perspective in cancer biology. Tissue Eng Part B Rev 16(3):351-359.
36. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D (1979) Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys 5(8):1225-1230.
37. Garofalo C, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30(24):2730-2740.
38. Hennessy BT, et al. (2010) A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6(4):129-151.